Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study

CONCLUSIONS: The RP2D for ceralasertib plus carboplatin was established as ceralasertib 40 mg QD on days 1-2 administered with carboplatin AUC5 every 3 weeks, with pharmacokinetic and pharmacodynamic studies confirming pharmacodynamic modulation and preliminary evidence of antitumor activity observed.PMID:34301752 | DOI:10.1158/1078-0432.CCR-21-1032

Source: Clinical Cancer Research - July 24, 2021 Category: Cancer & Oncology Authors: Timothy A Yap Matthew G Krebs Sophie Postel-Vinay Anthony El-Khouiery Jean-Charles Soria Juanita Lopez Alienor Berges S Y Amy Cheung Itziar Irurzun-Arana Andrew Goldwin Brunella Felicetti Gemma N Jones Alan Lau Paul Frewer Andrew J Pierce Glen Clack Chris Source Type: research